Navigation Links
Quorum Review IRB Executive Vice-Chair to Speak at DIA’s 49th Annual Meeting
Date:6/13/2013

Seattle, WA (PRWEB) June 13, 2013

Quorum Review IRB, the industry leader in central IRB services, announces its Executive Vice-Chair, Royce A. Morrison, MD, MS, as a presenter and panel chair at the Drug Information Association’s 49th Annual Meeting. This year DIA is held in Boston, MA, June 23-27, 2013.

Dr. Morrison chairs his first session “First-in-Human Studies: How Much Complexity Is Too Much?” on Tuesday, June 25 at 1:45 p.m. The meeting topic includes trends that disrupt standard early-phase sequences and drive study complexity, and the best practices to mitigate risks. Dr. Morrison focuses on “The IRB: Regulatory Protection” in his portion of the presentation. On Wednesday, June 26 at 10:15 a.m., Dr. Morrison chairs the session, “Pharmacometrics: Implications and Impact in Preclinical to Early Phase Clinical Development,” where panelists discuss the discipline of pharmacometrics in drug development and regulatory decision-making. Dr. Morrison will present “Opportunities to Take Advantage of Pharmacometrics” during that session. Later that afternoon at 4:00 p.m., he heads the panel discussion for “Pharmacometric Methods: Essential for Optimal Drug Development Strategy”. This session defines pharmacometrics and describes examples of its application across the range of drug and development and decision-making activities.

Dr. Morrison serves as Executive Vice-Chair on Quorum’s Review Board and is board certified in internal medicine as well as a Certified Physician Investigator by the Academy of Pharmaceutical Physicians and Investigators. He earned his MD degree at Stanford University and has practiced in both private and HMO settings, emphasizing geriatrics and HIV/AIDS. Dr. Morrison has been a member of the Board of Association of Clinical Pharmacology Units, and is Past President and Board member of the Northwest Association for Biomedical Research.

The DIA Annual Meeting is the largest multidisciplinary event that brings together a global network of professionals to foster innovation that will lead to the development of safe and effective medical products and therapies. More information about the 2013 conference is available on the DIA website.

For the latest on Quorum Review News and Events, visit http://www.quorumreview.com.

About Quorum Review IRB

Quorum Review is an independent review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing IRB review of drug and device trials since 1992. Quorum oversees research in accordance with U.S. and Canadian human subject research protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report.

Quorum’s best-in-class IRB services include 14 Board meetings each week plus expedited review, 24-hour site review turnaround, 36-hour amendment review turnaround, a secure web portal, and Smart Forms for online submissions. Quorum’s IRB service offerings include full study review in the US and Canada, a specialized Phase I team, and unique processes for post-approval and registry studies.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10819470.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Quorum Review IRB Launches Site Enrollment Service
2. Quorum Review IRB Presents “IRB Review of Registries, Databases and Biobanking” at 2013 AAHRPP Conference
3. Quorum Review IRB to Present “eConsent and the iPad: a Case Study” at Global ACRP Conference
4. Quorum Review IRB Presents on Good Clinical Practice Essentials at MAGI’s 2013 Clinical Research Conference
5. Quorum Review’s CEO Presents on IRB Response to Key Changes in Clinical Research Practice
6. Omega-3 Supplements No Help Against Repeat Heart Trouble: Review
7. AADR comments on review that validates association between oral health and heart health
8. IUDs Work as Emergency Contraceptive: Review
9. ICU stays for worst asthma drop 74 percent, review finds
10. Antiretroviral treatment for preventing HIV infection: an evidence review for physicians
11. TheBestHeartRateMonitorReviews.com Announces The Top 3 Heart Rate Monitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
(Date:3/29/2017)... ... ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, is now ... without a referral. Dr. Cotey knows that interceptive orthodontics in Mt. Horeb, ... receive early treatment, they may achieve straight teeth with less treatment in their teenage ...
(Date:3/29/2017)... Md., and MINNETONKA, Minn. (PRWEB) , ... March ... ... the development of medical office buildings (MOBs) and other outpatient facilities, and who ... project to look exclusively at those questions, Revista and Healthcare Real Estate Insights ...
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare ... team with prominent executives from both inside and outside the cannabis industry. , ... Dumbauld , who has more than twenty years of business leadership and investment experience ...
(Date:3/29/2017)... ... , ... HealthCareMandA.com will host an important webinar — Home Health & Hospice: ... recording of the webinar will also be made available following its live presentation. The ... are still popular targets for healthcare investors. This highly fragmented sector bounced back in ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017 Varian Medical Systems (NYSE: ... for the second quarter of fiscal year 2017 following the ... news release will be followed by a teleconference available to ... and a link to the conference call webcast will be ... access the teleconference call and replay: ...
(Date:3/29/2017)... AMSTERDAM , March 29, 2017   ... global leader in health technology, and PathAI, a ... are collaborating with the aim to develop solutions ... diagnosis of cancer and other diseases. The partnership ... pathology, enabling this form of artificial intelligence to ...
(Date:3/29/2017)... AVIV, Israel , March 29, 2017 ... agreement in which Exeltis will obtain exclusive marketing rights for Neurim,s ... ... an age-appropriate drug targeted to treat sleep disorders in children with ... be the first sleep medication approved for children. The ...
Breaking Medicine Technology: